Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of CGT9486 in advanced systemic mastocytosis
2024-511407-42-00Phase 2Authorised
- Sponsor
- Cogent Biosciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of bezuclastinib in systemic mastocytosis (SM) (3 arms), sponsored by Cogent Biosciences. Primary endpoints: Part 1 dose optimization: safety, PK/PD, and overall response rate, Part 2 stage 1 dose confirmation: safety, PK/PD, and overall response rate and 1 more. Planned start Jan 2022; status: authorised.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on 2024-511407-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511407-42-00.